Author

J. Niessl

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 5 Organism:human· 5 Approach:experimental assay· 4 Research Focus:clustering· 3 Assay:flow cytometry· 3 Research Focus:host-pathogen & immune response· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2

Frequent Co-Authors

C. Tremblay· 5 shared D. E. Kaufmann· 5 shared N. Brassard· 5 shared A. Finzi· 4 shared C. Morrisseau· 4 shared L. Gokool· 4 shared M. Dube· 4 shared M. Nayrac· 4 shared

Activity by Year

2021-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

C. Tremblay

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile

G. Sannier, A. Nicolas, M. Dube, L. Marchitto, M. Nayrac, O. Tastet, A. Tauzin, R. Lima-Barbosa, M. Laporte, R. Cloutier, A. S. Flores, M. Boutin, S. Y. Gong, M. Benlarbi, S. Ding, , D. E. Kaufmann

bioRxiv · Sep 5, 2022Immunology

A long interval between priming and boosting SARS-CoV-2 mRNA vaccine doses enhances B cell responses with limited impact on T cell immunity

A. Nicolas, G. Sannier, M. Dube, M. Nayrac, M. M. Painter, R. R. Goel, M. Laporte, H. R. Medjahed, J. Williams, N. Brassard, J. Niessl, L. Gokool, C. Morrisseau, P. Arlotto, C. Tremblay, , D. E. Kaufmann

This study shows that a longer interval between SARS-CoV-2 mRNA vaccine doses enhances B cell responses but has minimal impact on T cell immunity.

bioRxiv · Aug 3, 2022 · PreprintImmunology

Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen

M. Nayrac, M. Dube, G. Sannier, A. Nicolas, L. Marchitto, O. Tastet, A. Tauzin, N. Brassard, G. Beaudoin-Bussieres, D. Vezina, S. Y. Gong, M. Benlarbi, R. Gasser, A. Laumaea, C. Bourassa, , D. E. Kaufmann

The paper examines B and T cell immunity responses to a 16-week interval BNT162b2 vaccine regimen, finding robust immune memory and functional associations between immune components.

bioRxiv · Dec 18, 2021Immunology

Immune checkpoint expression on HIV-specific CD4+ T cells and response to their blockade are dependent on lineage and function

E. Brunet-Ratnasingham, A. Morou, M. Dube, J. Niessl, A. E. Baxter, O. Tastet, N. Brassard, G. Ortega-Delgado, R. Charlebois, G. J. Freeman, C. Tremblay, J.-P. Routy, D. E. Kaufmann

bioRxiv · Sep 23, 2021Immunology

A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses

A. Tauzin, M. Nayrac, M. Benlarbi, S. Y. Gong, R. Gasser, G. Beaudoin-Bussieres, N. Brassard, A. Laumaea, D. Vezina, J. Prevost, S. P. Anand, C. Bourassa, G. Gendron-Lepage, H. Medjahed, G. Goyette, , A. Finzi

This study shows a single dose of the BNT162b2 mRNA vaccine elicits strong antibody and T cell responses, including Fc-mediated effector functions, and boosts pre-existing immunity in previously infected individuals.

bioRxiv · Mar 18, 2021 · PreprintImmunology